Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

4.44
0.07 (1.60%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :127,952
Date :01-19-2021

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed to Present at H.C. Wainwright BioConnect 2021 Conference

January 7th, 2021|Comments Off on Oramed to Present at H.C. Wainwright BioConnect 2021 Conference

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will [...]

Oramed Reports Positive First in Human Data from Oral Leptin Study

December 23rd, 2020|Comments Off on Oramed Reports Positive First in Human Data from Oral Leptin Study

Leptin capsule may have a role in helping control and reduce obesity rates which are highly correlated with diabetes NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a [...]

Oramed Initiates Phase 2 NASH Trial of Oral Insulin

December 2nd, 2020|Comments Off on Oramed Initiates Phase 2 NASH Trial of Oral Insulin

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first [...]

Oramed Initiates Phase 3 Trial of Oral Insulin

November 24th, 2020|Comments Off on Oramed Initiates Phase 3 Trial of Oral Insulin

NEW YORK, Nov, 24, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened  the first patients in its [...]